CDT Equity (NASDAQ:CDT – Get Free Report) issued its earnings results on Wednesday. The company reported ($8.71) earnings per share (EPS) for the quarter, Zacks reports.
CDT Equity Price Performance
CDT stock traded down $0.21 during midday trading on Friday, reaching $2.93. The company had a trading volume of 21,012 shares, compared to its average volume of 296,223. The firm has a 50-day moving average price of $5.22 and a 200-day moving average price of $74.24. The company has a market capitalization of $1.85 million, a P/E ratio of -0.00 and a beta of 1.52. CDT Equity has a 1 year low of $2.53 and a 1 year high of $3,460.60.
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of CDT Equity in a report on Wednesday, June 24th. Wall Street Zen upgraded shares of CDT Equity from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.
About CDT Equity
Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Featured Articles
- Five stocks we like better than CDT Equity
- Sandisk’s Margins Look Like Software. Can They Last?
- CAVA Earnings: The Easiest Comp of the Year Meets a Tough Valuation
- Joint Operations: Curaleaf Makes a Play for Aurora Cannabis
- Cerebras Sells Off After Earnings: Is This a Market Disconnection?
Receive News & Ratings for CDT Equity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CDT Equity and related companies with MarketBeat.com's FREE daily email newsletter.
